Literature DB >> 25069980

Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Marina N Matos1, Silvia I Cazorla1, Augusto E Bivona1, Celina Morales2, Carlos A Guzmán3, Emilio L Malchiodi4.   

Abstract

In this work we immunized mice with DNA encoding full-length Tc52 or its amino- or carboxy-terminal (N- and C-term, respectively) domain carried by attenuated Salmonella as a DNA delivery system. As expected, Salmonella-mediated DNA delivery resulted in low antibody titers and a predominantly Th1 response, as shown by the ratio of IgG2a/IgG1-specific antibodies. Despite modest expression of Tc52 in trypomastigotes, the antibodies elicited by vaccination were able to mediate lysis of the trypomastigotes in the presence of complement and inhibit their invasion of mammal cells in vitro. The strongest functional activity was observed with sera from mice immunized with Salmonella carrying the N-term domain (SN-term), followed by Tc52 (STc52), and the C-term domain (SC-term). All immunized groups developed strong cellular responses, with predominant activation of Th1 cells. However, mice immunized with SN-term showed higher levels of interleukin-10 (IL-10), counterbalancing the inflammatory reaction, and also strong activation of Tc52-specific gamma interferon-positive (IFN-γ(+)) CD8(+) T cells. In agreement with this, although all prototypes conferred protection against infection, immunization with SN-term promoted greater protection than that with SC-term for all parameters tested and slightly better protection than that with STc52, especially in the acute stage of infection. We conclude that the N-terminal domain of Tc52 is the section of the protein that confers maximal protection against infection and propose it as a promising candidate for vaccine development.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25069980      PMCID: PMC4187887          DOI: 10.1128/IAI.02190-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor.

Authors:  Margarida Borges; Anabela Cordeiro Da Silva; Denis Sereno; Ali Ouaissi
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 2.  Genetic immunization: bacteria as DNA vaccine delivery vehicles.

Authors:  Pablo Daniel Becker; Miriam Noerder; Carlos Alberto Guzmán
Journal:  Hum Vaccin       Date:  2010-05-14

3.  A recombinant Salmonella typhimurium vaccine strain is taken up and survives within murine Peyer's patch dendritic cells.

Authors:  S A Hopkins; F Niedergang; I E Corthesy-Theulaz; J P Kraehenbuhl
Journal:  Cell Microbiol       Date:  2000-02       Impact factor: 3.715

4.  Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Authors:  Paula Ordonhez Rigato; Bruna C de Alencar; José Ronnie C de Vasconcelos; Mariana R Dominguez; Adriano F Araújo; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2011-02-28       Impact factor: 3.441

5.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

Review 6.  Emerging Chagas disease in Amazonian Brazil.

Authors:  José Rodrigues Coura; Angela C V Junqueira; Octavio Fernandes; Sebastiao A S Valente; Michael A Miles
Journal:  Trends Parasitol       Date:  2002-04

7.  Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier.

Authors:  A Darji; S zur Lage; A I Garbe; T Chakraborty; S Weiss
Journal:  FEMS Immunol Med Microbiol       Date:  2000-04

8.  Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy.

Authors:  J Koesling; B Lucas; L Develioglou; T Aebischer; T F Meyer
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

9.  The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection.

Authors:  Ali Ouaissi; Eliane Guilvard; Yves Delneste; Gersende Caron; Giovanni Magistrelli; Nathalie Herbault; Nathalie Thieblemont; Pascale Jeannin
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

Review 10.  The role of parasite persistence in pathogenesis of Chagas heart disease.

Authors:  F R S Gutierrez; P M M Guedes; R T Gazzinelli; J S Silva
Journal:  Parasite Immunol       Date:  2009-11       Impact factor: 2.280

View more
  10 in total

1.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.

Authors:  Natacha Cerny; Andrés Sánchez Alberti; Augusto E Bivona; Mauricio C De Marzi; Fernanda M Frank; Silvia I Cazorla; Emilio L Malchiodi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.

Authors:  Marina N Matos; Silvia I Cazorla; Kai Schulze; Thomas Ebensen; Carlos A Guzmán; Emilio L Malchiodi
Journal:  PLoS Negl Trop Dis       Date:  2017-02-24

4.  Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against Trypanosoma cruzi.

Authors:  Natacha Cerny; Augusto Ernesto Bivona; Andrés Sanchez Alberti; Sebastián Nicolás Trinitario; Celina Morales; Alejandro Cardoso Landaburu; Silvia Inés Cazorla; Emilio Luis Malchiodi
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 5.  Vaccine Design against Chagas Disease Focused on the Use of Nucleic Acids.

Authors:  Edio Maldonado; Sebastian Morales-Pison; Fabiola Urbina; Aldo Solari
Journal:  Vaccines (Basel)       Date:  2022-04-12

6.  Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.

Authors:  Andrés Sanchez Alberti; Augusto E Bivona; Natacha Cerny; Kai Schulze; Sebastian Weißmann; Thomas Ebensen; Celina Morales; Angel M Padilla; Silvia I Cazorla; Rick L Tarleton; Carlos A Guzmán; Emilio L Malchiodi
Journal:  NPJ Vaccines       Date:  2017-04-10       Impact factor: 7.344

7.  Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.

Authors:  Augusto E Bivona; Andrés Sánchez Alberti; Marina N Matos; Natacha Cerny; Alejandro C Cardoso; Celina Morales; Germán González; Silvia I Cazorla; Emilio L Malchiodi
Journal:  PLoS Negl Trop Dis       Date:  2018-03-30

8.  The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms.

Authors:  Lucas D Caeiro; Catalina D Alba-Soto; Mariana Rizzi; María Elisa Solana; Giselle Rodriguez; Agustina M Chidichimo; Matías E Rodriguez; Daniel O Sánchez; Gabriela V Levy; Valeria Tekiel
Journal:  PLoS Negl Trop Dis       Date:  2018-05-04

9.  Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.

Authors:  María Belén Antonoglou; Andrés Sánchez Alberti; Daniela María Redolfi; Augusto Ernesto Bivona; María Julieta Fernández Lynch; Sofía Noli Truant; María Belén Sarratea; Laura Valeria Iannantuono López; Emilio Luis Malchiodi; Marisa Mariel Fernández
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

10.  Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi.

Authors:  Andrés Sanchez Alberti; Augusto E Bivona; Marina N Matos; Natacha Cerny; Kai Schulze; Sebastian Weißmann; Thomas Ebensen; Germán González; Celina Morales; Alejandro C Cardoso; Silvia I Cazorla; Carlos A Guzmán; Emilio L Malchiodi
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.